Breast cancer, placing drug interactions in the spotlight: is polypharmacy the cause of everything?

José Alberto Domínguez Alonso; David Conde Estévez; David Bosch Ros; Maria Pi-Figueras; Ignacio Tusquets Trias de Bes

Ayuda

Breast cancer, placing drug interactions in the spotlight: is polypharmacy the cause of everything?

José Alberto Domínguez-Alonso ^[1] ; David Conde-Estévez ^[2] ; David Bosch ^[3] ; Maria Pi-Figueras ^[2] ; Ignacio Tusquets ^[2]
1. [1] Universitat Pompeu Fabra
  
  Universitat Pompeu Fabra
  
  Barcelona, España
2. [2] Hospital del Mar
  
  Hospital del Mar
  
  Barcelona, España
3. [3] Universitat de Barcelona
  
  Universitat de Barcelona
  
  Barcelona, España
Mostrar afiliaciones +
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 1 (January), 2021, págs. 65-73
Idioma: inglés
Texto completo no disponible (Saber más ...)
Resumen
- Purpose Breast cancer is the most prevalent and lethal cancer among women. Forty-one percent of cases occur in people ≥ 70 years, hindering their treatment given its comorbidities and polypharmacy (PP). Potential drug–drug interactions (PDDI) were analyzed in elderly breast cancer patients between daily and oncospecific treatments and their associations with Age, BMI, Mini Nutritional Assessment (MNA), Frailty categorization, PP, and adverse effects.
  
  Patients/methods A cohort of 77 patients ≥ 70 years with breast cancer who underwent a Comprehensive Geriatric Assessment (CGA) were included. Clinical characteristics were collected using medical records. PDDI between treatments were analyzed using two databases. Data were assessed using linear regression, Chi-square, Mann–Whitney U, and Kruskal–Wallis tests. Finally, a multivariate logistic regression model was built and tested to predict adverse effects.
  
  Results From 719 PDDI, 530 (74%) were moderate (r2 = 0.72) and the median number of drugs during oncospecific treatment (r2 = 0.73) was 9 (range 3–26). Overall, 59 patients (77%) had adverse effects associated with Frailty categorization and MNA (p < 0.05). The distribution of major, moderate, minor, and total PDDI was associated with PP at CGA and during oncospecific treatment (p < 0.05). Moreover, it was verified that Frailty categorization protects from adverse effects given the intervention made at CGA.
  
  Conclusions CGA should be applied in oncologic elderly patients to assess clinical outcomes and categorize them according to their frailty but also to analyze PDDI. Furthermore, we encourage the use of the model in clinical practice for predicting the occurrence of adverse effects, improving therapeutic conciliation.